Evolution & AI
for
Precision cancer prognostics
Leveraging Artificial Intelligence with evolutionary insights to design precision diagnostics for cancer malignancy.
Your body is the soil in which cancer can grow
Using decades of research at Yale, Johns Hopkins, and UConn, we bring a revolutionary way to predict your body’s capability to prevent, or assist cancer spread
From Evolutionary Insights to Life-Changing Applications
Cancer Metastasis Prediction Test
- Designed for clinical guidance
- Predicts metastatic risk for more personalized oncology care
- Assist definition of resection margin for surgery of primary tumor
Preventative Tracking of Metastatic Risk
- Designed for cancer survivors, and with family history of cancer.
- Your body’s early warning test for cancer
- Food, toxins, hormonal imbalances, menopause, obesity — all affect your body’s stroma’s capability to resist cancer spread.
- Actionable insights to improve stromal health by lifestyle choices.
StromaScope : In vitro Profiling for Stromal Risk to Metastasis
Designed for Pharma R&D, CROs, Toxicology- Off-target effect on tissue stroma are understudied for most drugs
- Preclinical models miss subtle microenvironmental effects
- Quantitative assay fills the gap between cytotoxicity and in vivo pathology
Evolutionary Medicine - Learning from Nature to Decode Cancer Risk
Evolutionary Medicine
Nature has had a billion years to perfect its ways.
When cows and horses get cancer, it stays in its primary location, and the animal does not suffer or die!
Scientists at OncoBarrier have used evolution to understand why the same cancer spreads fast in some people, and slowly in others. A revolutionary approach, unlike any other.
Your genetics, diet, hormones, stress — everything affects your body’s ability to prevent cancer spread.
It is an empowering message: you may not control the genetics of your cancer, but you can take control of the soil of your body.
ELI
Evolved Levels of Invasibility is a revolutionary scientific advancement based on evolutionary medicine. ELI is the science of why some animals prevent cancer from spreading. The same cancer spreads fast in some people, and slowly in others. It is to do with your soil, your body.
Our Technology
Predicting how vulnerable are you to cancer spread?
The state of your body has a profound effect on how cancer spreads. Obesity, inflammation, chronic stress, and genetics — all can change the soil to be vulnerable for cancer to grow.
We use large omics datasets of patients to create our unique evolutionary framework to map a person’s cellular state to their risk of cancer spread.
How it works:
- Transcriptomics: Identifying gene expression patterns tied to your body’s resilience or vulnerability based on Evolutionary Medicine.
- AI and Genomics: Combining cutting-edge graph deep learning with evolutionary insights for precise diagnostics.
- Nanotech Cellular Testing : Using our nanotextured device, we will directly test your healthy cell’s inherent ability to resist cancer.
We have analyzed data from many animals to identify genes which protect us from malignancy, and those that promote.
Our proprietary and public data from thousands of patients is then fed into our powerful AI model based on our unique evolutionary insights to predict —- what chance do you have for your cancer to become malignant.
AI Powered Prognostics
Genetics cannot explain everything about cancer malignancy. Huge variability exists between patients in their susceptibility to cancer metastasis.
For breast cancer, for example, obesity is a big risk factor as well as metabolic syndrome. OncoBarrier has developed an AI powered stratification based on evolution of vulnerability to cancer malignancy.
Pipeline
Our flagship product builds on both basic research and empirical evidence from patient samples and data. We’re gearing forward with safety and efficacy data to an Investigational Drug licensing.
People
We bring decades of cumulative research in Artificial Intelligence, Cancer Malignancies, Evolutionary Medicine, with ground breaking publications in prestigious journals. The technology is developed by research investments of $6 Million from National Cancer Institute, Temple Foundation, and National Institute of Child Health and Development.
Kshitiz, Ph.D., Founder
Associate Professor in Cancer Biology UConn Health
Previous: CTO, Cardiac Mimetics
Ass Res Scientist, Yale University
PhD, BME, Johns Hopkins Medicine
B.Tech., Computer Science, IIT Bombay
GÜnter Wagner, co-Founder
Evolutionary Medicine
Yasir Suhail, co-Founder
Artificial Intelligence & Bioinformatics
Previous: Postdoc, Yale University PhD, BME, Johns Hopkins Medicine B.Tech., EE, IIT Delhi
Publications
